Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Ajay Major MD, MBA

Ajay Major MD, MBA

Assistant Professor, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado

Dr. Ajay Major is an assistant professor at the University of Colorado School of Medicine specializing in lymphoma, with expertise in indolent non-Hodgkin lymphomas and CLL/SLL. He is a patient-reported outcomes (PROs) methodologist and his outcomes and health services research focuses on using PROs to measure health-related quality of life, treatment tolerability, and the short- and long-term symptom burden from lymphoma and anti-cancer therapies throughout survivorship.

Disclosures

Dr. Major reports the following: Incyte (research funding), GSK (research funding), and Genentech (consulting).

Recent Contributions to PracticeUpdate:

  1. Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Most Read This Week

Recently Updated